Pfizer announced on Monday it was discontinuing the development of one of its obesity pill candidates due to elevated levels of liver enzymes being detected during clinical trials, while the development of another obesity pill is set to continue. The pharmaceutical company has been developing two oral treatments for treating obesity and type 2 diabetes mellitus, danuglipron and lotiglipron. According to Pfizer, elevated levels of the enzyme transaminase were detected during both Phase 1 and Phase 2 studies for lotiglipron. Higher levels of this enzyme can indicate liver disease or drug-induced liver damage. Despite these observations, Pfizer said none of the trial participants expe
Hence then, the article about pfizer discontinues development of obesity pill due to elevated liver enzymes was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Pfizer discontinues development of obesity pill due to elevated liver enzymes )